Related references
Note: Only part of the references are listed.Association of Serum Levels of CEA, CA199, CA125, CYFRA21-1 and CA72-4 and Disease Characteristics in Colorectal Cancer
Wa Zhong et al.
PATHOLOGY & ONCOLOGY RESEARCH (2015)
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update
M. J. Duffy et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Molecular Alterations and Biomarkers in Colorectal Cancer
William M. Grady et al.
TOXICOLOGIC PATHOLOGY (2014)
Evaluation of preoperative serum markers for individual patient prognosis in stage I-III rectal cancer
Clemens Giessen et al.
TUMOR BIOLOGY (2014)
Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer
Hui-Yan Luo et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Colorectal cancer surveillance: What's new and what's next?
Johnie Rose et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
The role of tumour markers and biomarkers in colorectal cancer
G. Lech et al.
NEOPLASMA (2014)
Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
J. M. Juergensmeier et al.
BRITISH JOURNAL OF CANCER (2013)
Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Colorectal Cancer Biomarkers and the Potential Role of Cancer Stem Cells
Russell C. Langan et al.
JOURNAL OF CANCER (2013)
Evaluation of predictive markers for patients with advanced colorectal cancer
Per Bystrom et al.
ACTA ONCOLOGICA (2012)
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
H. J. Schmoll et al.
ANNALS OF ONCOLOGY (2012)
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
Xiaoyun Liao et al.
CLINICAL CANCER RESEARCH (2012)
PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Arjun Sood et al.
CLINICAL COLORECTAL CANCER (2012)
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
Carsten Bokemeyer et al.
EUROPEAN JOURNAL OF CANCER (2012)
Ezrin expression in rectal cancer predicts time to development of local recurrence
Fredrik Jorgren et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2012)
Chromosomal Instability (CIN) Phenotype, CIN High or CIN Low, Predicts Survival for Colorectal Cancer
Toshiaki Watanabe et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
Sabine Tejpar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
Kjell Magne Tveit et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis
Mafalda M. Dias et al.
PHARMACOGENOMICS (2012)
Clinical Implications of UGT1A1*28 Genotype Testing in Colorectal Cancer Patients
Katerina Shulman et al.
CANCER (2011)
Molecular Tests for Colorectal Cancer Screening
Linda J. W. Bosch et al.
CLINICAL COLORECTAL CANCER (2011)
Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer
Timothy J. Price et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
Gordon Hutchins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
C-stage in Colon Cancer: Implications of Carcinoembryonic Antigen Biomarker in Staging, Prognosis, and Management
Pragatheeshwar Thirunavukarasu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
Timothy S. Maughan et al.
LANCET (2011)
Ezrin Expression as a Prognostic Marker in Colorectal Adenocarcinoma
Marcelo Patara et al.
PATHOLOGY & ONCOLOGY RESEARCH (2011)
Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals
Hans J. Nielsen et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2011)
Clinical utility of serum tumor markers in the diagnosis of malignant intestinal occlusion. A prospective observational study
Daniele Marrelli et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2011)
Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up
R. Labianca et al.
ANNALS OF ONCOLOGY (2010)
Intensive Risk-Adjusted Follow-up With the CEA, TPA, CA19.9, and CA72.4 Tumor Marker Panel and Abdominal Ultrasonography to Diagnose Operable Colorectal Cancer Recurrences Effect on Survival
Andrea Nicolini et al.
ARCHIVES OF SURGERY (2010)
Fecal MicroRNAs as Novel Biomarkers for Colon Cancer Screening
Alexander Link et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2010)
MicroRNA Expression Profiling of Exfoliated Colonocytes Isolated from Feces for Colorectal Cancer Screening
Yoshikatsu Koga et al.
CANCER PREVENTION RESEARCH (2010)
NRAS Mutations Are Rare in Colorectal Cancer
Natsumi Irahara et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2010)
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Wendy De Roock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Arnaud D. Roth et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Biomarkers to predict the clinical efficacy of bevacizumab in cancer
Adrian M. Jubb et al.
LANCET ONCOLOGY (2010)
Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery
Sabine Tejpar et al.
ONCOLOGIST (2010)
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
Andrea Sartore-Bianchi et al.
CANCER RESEARCH (2009)
Clinical implications of microsatellite instability in sporadic colon cancers
Frank A. Sinicrope et al.
CURRENT OPINION IN ONCOLOGY (2009)
Prognostic Significance and Molecular Associations of 18q Loss of Heterozygosity: A Cohort Study of Microsatellite Stable Colorectal Cancers
Shuji Ogino et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803
Monica M. Bertagnolli et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan
Erika Cecchin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
PIK3CA Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
Shuji Ogino et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Analysis of Fecal DNA Methylation to Detect Gastrointestinal Neoplasia
Takeshi Nagasaka et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer
Salvatore Siena et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Molecular Origins of Cancer: Molecular Basis of Colorectal Cancer.
Sanford D. Markowitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Quantitative fluorescence determination of long-fragment DNA in stool as a marker for the early detection of colorectal cancer
Daniele Calistri et al.
CELLULAR ONCOLOGY (2009)
Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
E. Rouits et al.
BRITISH JOURNAL OF CANCER (2008)
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
Minaxi Jhawer et al.
CANCER RESEARCH (2008)
Detection of colorectal cancer cells from feces using quantitative real-time RT-PCR for colorectal cancer diagnosis
Yoshikatsu Koga et al.
CANCER SCIENCE (2008)
Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention
K. Koss et al.
COLORECTAL DISEASE (2008)
Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients
Frank Diehl et al.
GASTROENTEROLOGY (2008)
Quantitative Real-time RT-PCR Detection for Survivin, CK20 and CEA in Peripheral Blood of Colorectal Cancer Patients
ChangXin Shen et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study
Franco Berrino et al.
LANCET ONCOLOGY (2007)
Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps
Wai K. Leung et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
F. Di Fiore et al.
BRITISH JOURNAL OF CANCER (2007)
Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study
George P. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
Gershon Y. Locker et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Molecular detection of circulating tumor cells in the peripheral blood of patients with colorectal cancer using RT-PCR: Significance of the prediction of postoperative metastasis
Jaw-Yuan Wang et al.
WORLD JOURNAL OF SURGERY (2006)
Critical evaluation of real-time reverse transcriptase-polymerase chain reaction for the quantitative detection of cytokeratin 20 mRNA in colorectal cancer patients
N Dandachi et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2005)
The TP53 Colorectal Cancer International Collaborative Study on the prognostic and predictive significance of p53 mutation:: Influence of tumor site, type of mutation, and adjuvant treatment
A Russo et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
CC Chen et al.
JOURNAL OF SURGICAL RESEARCH (2005)
Stool screening for colorectal cancer: Molecular approaches
NK Osborn et al.
GASTROENTEROLOGY (2005)
Systematic review of microsatellite instability and colorectal cancer prognosis
S Popat et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis
S Popat et al.
EUROPEAN JOURNAL OF CANCER (2005)
Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q
L Sarli et al.
DISEASES OF THE COLON & RECTUM (2004)
CEA, CA 242, CA 19-9, CA 72-4 and hCG beta in the diagnosis of recurrent colorectal cancer
M Carpelan-Holmstrom et al.
TUMOR BIOLOGY (2004)
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
CM Ribic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Hepatic resection for colorectal metastases: Can preoperative scoring predict patient outcome?
T Mala et al.
WORLD JOURNAL OF SURGERY (2002)
Detection of APC mutations in fecal DNA from patients with colorectal tumors
G Traverso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
T Watanabe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer
H Elsaleh et al.
LANCET (2000)
Indicators for treatment strategies of colorectal liver metastases
H Ueno et al.
ANNALS OF SURGERY (2000)
Share Paper
